Hematology/Oncology

Top Story

Early treatment shows long-term benefit for high-risk smoldering myeloma

Early treatment shows long-term benefit for high-risk smoldering myeloma
August 29, 2016

Early treatment with lenalidomide plus dexamethasone prolonged time to progression and OS compared with observation for patients with high-risk smoldering multiple myeloma, according to long-term follow-up results of the phase 3 QuiRedex trial.

“The standard of care for most patients with smoldering multiple myeloma is observation until the development of myeloma-defining events,” Maria-Victoria Mateos, MD, PhD, associate professor of hematology at Instituto do Investigación Biomédica de Salamanca in Salamanca, Spain, and colleagues wrote. “However, this no-treatment approach, which was probably suitable in the era of restricted treatment options also associated with notable toxic effects, might not be the best options in a new era of myeloma treatment.”

Extended work hours increase risk for cancer among U.S. women

August 29, 2016
Women in the United States who worked at least 60 hours per week during the span of 3 decades demonstrated increased risk for cancer and other chronic health problems…
In the Journals Plus

Timing between thyroidectomy, radioactive iodine does not affect DTC outcomes

August 29, 2016
Disease outcomes in differentiated thyroid cancer, or DTC, are not influenced by the time between total thyroidectomy and radioactive iodine dosing, study data show. …
In the Journals Plus

Longer continuous docetaxel treatment confers OS benefit in prostate cancer

August 29, 2016
A greater number of docetaxel cycles improved OS in men with metastatic castration-resistant prostate cancer, according to a post-hoc analysis of the phase 3 Mainsail…
Meeting News CoverageVideo

VIDEO: William J. Gradishar, MD, FASCO, FACP, reviews benefits, role of CDK 4/6 inhibitors

August 28, 2016
Results of the phase 2, single-arm MONARCH1 trial of abemaciclib demonstrated safety and efficacy and provided context in regard to how it fits in with other CDK 4/6…
More News Headlines »
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Video
At Issue

VIDEO: Immune checkpoint inhibitors show promise in metastatic, triple-negative breast cancer

August 9, 2016
More »
Featured
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer

CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Current Issues
View the Current Issue
HemOnc Today